Streetbeat News

Products Services

FWRD

Forward Air Corporation (NASDAQ:FWRD) announced a 5.9% general rate increase for shipments starting February 5, 2024. This adjustment is to support continued investment in customer support, safety, and service enhancements amid rising operating costs in the freight transportation industry, including real estate, equipment, cost per mile, and inflation. Forward Air is known for its expedited less-than-truckload (LTL) services, on-time performance, speed, and low damage rates.

Portfolio Pulse from Benzinga Newsdesk

December 11, 2023 | 2:28 pm

CALT

Calliditas Therapeutics AB received a notice of allowance for a US patent application covering a method of treating IgA nephropathy with TARPEYO® (budesonide) delayed release capsules. The anticipated patent, expiring in 2043, will be the second US patent for TARPEYO and is expected to be Orange Book-listable. Calliditas plans to seek similar protections in other territories, including Europe and China, to strengthen TARPEYO's intellectual property and support the global NEFECON® franchise.

Portfolio Pulse from Benzinga Newsdesk

December 11, 2023 | 2:22 pm

SNOW

Snowflake (NYSE:SNOW) has received FedRAMP High Authorization on AWS GovCloud, enabling it to handle sensitive unclassified federal data. This authorization allows Snowflake to offer its Government & Education Data Cloud for various government workloads and critical data analytics. Snowflake also announced enhanced governance capabilities with Snowflake Horizon at its 2023 Snowday event. The platform supports regulated workloads and enables secure data sharing for public sector organizations.

Portfolio Pulse from Benzinga Newsdesk

December 11, 2023 | 2:20 pm

WKEY

WISeKey International's subsidiary, WISeSat.Space, is reinforcing its space strategy by engaging in strategic partnerships and innovative projects with various entities including Fossa Systems, the Swiss Armed Forces, PLD Space, SpaceX, and Dubai Port DP World. These collaborations aim to enhance WISeKey's position in the space industry.

Portfolio Pulse from Benzinga Newsdesk

December 11, 2023 | 2:15 pm

SHPH

Shuttle Pharmaceuticals has submitted an Investigational New Drug (IND) application to the FDA for a Phase II clinical trial of Ropidoxuridine in patients with Glioblastoma, a type of brain cancer.

Portfolio Pulse from Benzinga Newsdesk

December 11, 2023 | 2:13 pm

BTOG

Bit Origin has secured a $6.74 million investment for constructing a new 25 MW crypto mining data center in Cheyenne, Wyoming. The company expects the data center to be completed by early Q2 2024 and to house between 4,480 to 8,400 bitcoin miners. This expansion is anticipated to significantly boost Bit Origin's revenue and cash flow starting in the second half of 2024. Additionally, Bit Origin has entered into a securities purchase agreement to sell up to $24.74 million of convertible notes and warrants to ATW Digital Assets Opportunity.

Portfolio Pulse from Benzinga Newsdesk

December 11, 2023 | 2:10 pm

AZN

KTTA

PFE

Pasithea Therapeutics Corp (KTTA) reported positive preclinical results for its cancer treatment PAS-004, showing superior efficacy compared to treatments from Pfizer (PFE) and AstraZeneca (AZN). KTTA's stock soared over 150% in premarket trading. The company aims to begin Phase 1 trials in early 2024 pending FDA IND acceptance.

Portfolio Pulse from Vandana Singh

December 11, 2023 | 2:05 pm

COIN

Coinbase Global Inc (NASDAQ:COIN) stock is trading lower due to a decline in Bitcoin's price after a recent surge. Bitcoin's pullback is attributed to profit-taking following a 13% rally over the past week and a 150% increase year-to-date. The broader crypto market's rally has been driven by institutional interest and expectations of a potential Bitcoin ETF and a pause in Federal Reserve rate hikes. Despite the drop, Coinbase shares are still up 60% over the last month.

Portfolio Pulse from Adam Eckert

December 11, 2023 | 1:58 pm

AZN

AstraZeneca Plc (NASDAQ:AZN) announced positive results from the ALPHA Phase 3 trial of danicopan as an add-on therapy to Ultomiris or Soliris in PNH patients. The trial showed sustained clinical benefits, including improved hemoglobin and ARC levels, and met all key secondary endpoints. Danicopan was well tolerated with no new safety concerns. AZN shares saw a slight increase of 0.28% in premarket trading.

Portfolio Pulse from Vandana Singh

December 11, 2023 | 1:58 pm

UBER

Uber Technologies has entered into a delivery partnership with Torchy's Tacos, adding over 100 restaurant locations across 14 states to the Uber Eats app for delivery services.

Portfolio Pulse from Benzinga Newsdesk

December 11, 2023 | 1:54 pm